← Astrana Health, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | ($9.3m) | $25.8m | $10.8m | $14.1m | $37.9m | $73.9m | $50.5m | $60.7m | $43.1m | $22.5m | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($8.2m) | $45.8m | $60.3m | $17.7m | $122.3m | $49.3m | — | $57.8m | $49.9m | $24.1m | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $1.2m | $20.0m | $49.4m | $3.6m | $84.5m | ($24.6m) | — | ($2.9m) | $6.8m | $1.6m | |
| Depreciation, Depletion and Amortization | $351k | $19.1m | $19.3m | $18.8m | $18.4m | $17.5m | $17.5m | $17.7m | $27.9m | $45.7m | |
| Amortization | $95k | — | — | — | — | — | — | — | — | — | |
| Amortization of Debt Issuance Costs | — | — | $0 | $473k | $1.3m | $1.1m | $939k | $1.1m | $1.8m | $4.0m | |
| Amortization of Intangible Assets | — | — | — | $16.3m | $16.0m | $15.4m | — | $12.7m | $25.6m | $40.7m | |
| Deferred Income Tax Expense (Benefit) | ($128k) | ($20.7m) | ($8.3m) | ($6.8m) | ($6.6m) | ($6.0m) | — | ($12.4m) | ($4.2m) | ($4.3m) | |
| Share-based Payment Arrangement, Noncash Expense | — | — | — | $1.5m | $3.4m | $6.7m | — | $22.0m | $34.5m | $38.6m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | — | — | $4.7m | $6.2m | |
| Share-based Payment Arrangement, Expense | $1.1m | $2.7m | $1.4m | $607k | $3.4m | $6.7m | — | $22.0m | $34.5m | $38.6m | |
| Equity Method Investment, Other than Temporary Impairment | — | — | — | — | $0 | ($2.8m) | $901k | $0 | $0 | $0 | |
| Goodwill and Intangible Asset Impairment | $207k | $2.4m | $3.8m | $2.0m | $0 | $0 | — | — | — | — | |
| Goodwill, Impairment Loss | $546k | — | $3.8m | $3.8m | $0 | $0 | — | $0 | $0 | $0 | |
| Impairment of Intangible Assets (Excluding Goodwill) | $281k | — | — | — | — | $0 | — | $0 | $0 | — | |
| Impairment of Intangible Assets, Finite-lived | — | $3.2m | $0 | $0 | $0 | — | — | — | $0 | $0 | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | — | — | $2.0m | $0 | $0 | — | $0 | $0 | $0 | |
| Equity Method Investment, Realized Gain (Loss) on Disposal | — | — | — | — | $99.8m | $2.2m | $901k | $0 | $0 | — | |
| Gain (Loss) on Disposition of Assets | ($477k) | — | — | — | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | ($42k) | $0 | ($91k) | $0 | — | — | — | — | |
| Gain (Loss) on Extinguishment of Debt | ($266k) | $0 | — | — | — | — | $0 | $0 | $2.4m | — | |
| Income (Loss) from Equity Method Investments | — | ($1.1m) | ($8.1m) | ($6.9m) | $3.7m | ($4.3m) | $901k | $5.6m | $4.5m | $1.7m | |
| Income Tax Expense (Benefit) | ($71k) | $3.9m | $22.4m | $8.2m | $56.1m | $28.5m | — | $32.0m | $30.9m | $15.5m | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $33.1m | $49.9m | |
| Other Nonoperating Income (Expense) | $239k | $168k | $1.6m | $3.0m | $1.1m | ($3.8m) | — | $6.1m | $4.9m | ($2.8m) | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | $27k | ($10.7m) | $263k | ($10.7m) | ($4.1m) | $1.5m | — | $26.7m | $44.4m | $9.4m | |
| Equity Securities, FV-NI, Gain (Loss) | — | — | — | — | — | — | — | $6.6m | ($135k) | — | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | ($4.1m) | ($146k) | — | |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | $11k | ($10.8m) | $25.5m | $2.6m | $11k | — | |
| Gain (Loss) on Investments | — | $13.7m | $0 | $0 | $99.8m | $10.8m | $25.5m | $4.8m | ($731k) | — | |
| Gain (Loss) on Sale of Financing Receivable | — | $922k | $0 | $0 | — | — | — | — | — | — | |
| General and Administrative Expense | $17.0m | $26.4m | $43.4m | $41.5m | $49.1m | $62.1m | — | $112.6m | $154.1m | $217.3m | |
| Goodwill | $1.6m | $189.8m | $185.8m | $238.5m | $239.1m | $253.0m | $245.8m | $278.8m | $419.3m | $865.3m | |
| Investment Income, Interest | — | $1.0m | $1.3m | $2.0m | $2.8m | $1.6m | — | $14.2m | $14.5m | $12.2m | |
| Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims | — | — | — | — | $306.6m | $348.3m | — | $852.9m | $1.3b | $1.9b | |
| Nonoperating Income (Expense) | ($978k) | $14.6m | ($5.8m) | ($6.6m) | $97.9m | ($20.4m) | — | $5.2m | ($8.5m) | ($38.9m) | |
| Operating Expenses | $51.3m | $322.6m | $431.5m | $528.2m | — | — | — | — | — | — | |
| Proceeds from Stock Options Exercised | — | $165k | — | — | — | — | — | — | — | — | |
| Unrealized Gain (Loss) on Derivatives | — | — | — | — | $11k | — | — | $201k | $0 | — | |
| Unrealized Gain (Loss) on Investments | — | $86k | ($25k) | $9k | ($11k) | ($10.7m) | $25.5m | ($4.6m) | $731k | ($68k) | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | ($409k) | ($45k) | $0 | $0 | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | $21.9m | $51.9m | $25.5m | $13.7m | $46.2m | $70.3m | $82.1m | $68.2m | $52.2m | $114.6m | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $262k | $2.1m | $1.2m | $1.0m | $1.2m | $19.2m | $22.9m | $28.5m | $8.0m | $10.1m | |
| Payments to Acquire Businesses, Net of Cash Acquired | $0 | $0 | $0 | $49.4m | $11.4m | $2.6m | $16.4m | $6.5m | $146.3m | $548.6m | |
| Payments for (Proceeds from) Other Investing Activities | — | — | — | — | — | — | — | — | — | ($6.3m) | |
| Net Cash Provided by (Used in) Investing Activities | ($247k) | $8.0m | ($25.2m) | ($180.6m) | $95.5m | $16.5m | ($7.1m) | ($65.5m) | ($192.4m) | ($539.0m) | |
| Cash flows from financing activities: | |||||||||||
| Proceeds from Issuance of Long-term Debt | — | — | — | $250.0m | — | — | — | — | — | — | |
| Repayments of Long-term Debt | — | $0 | $0 | $2.4m | $0 | $201k | $3.9m | — | — | — | |
| Proceeds from Issuance of Common Stock | $200k | $2.2m | $200k | $755k | $0 | $40.1m | — | $0 | — | — | |
| Payments for Repurchase of Common Stock | — | $3.2m | $5.0m | $7.6m | $537k | $5.7m | — | $10.2m | $900k | $25.6m | |
| Payments of Ordinary Dividends, Common Stock | — | $10.4m | $17.8m | $61.7m | $51.3m | $31.1m | — | $62.1m | $4.0m | $7.9m | |
| Proceeds from Noncontrolling Interests | $0 | — | — | — | — | — | — | — | — | — | |
| Proceeds from (Payments to) Noncontrolling Interests | — | $0 | $27k | $28k | $0 | $48k | — | $0 | $150k | — | |
| Dividends Payable, Current | — | — | — | $271k | $485k | $556k | — | $638k | $638k | — | |
| Dividends Payable | — | — | — | $271k | $485k | $71k | — | $0 | — | — | |
| Proceeds from (Payments for) Other Financing Activities | — | ($9.0m) | $0 | $0 | — | — | — | — | — | $2.3m | |
| Net Cash Provided by (Used in) Financing Activities | $6.3m | ($15.0m) | ($11.2m) | $163.3m | ($51.7m) | ($47.7m) | ($20.1m) | $3.4m | $135.1m | $569.3m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | $63.6m | ($10.9m) | ($3.6m) | $90.0m | $39.1m | $54.9m | $6.1m | ($5.1m) | $144.9m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $63.6m | $107.6m | $104.0m | $194.0m | $233.1m | $54.9m | $294.2m | $289.1m | $434.0m | |
| Restricted Cash and Investments, Current | $530k | — | — | — | — | — | — | — | — | — | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $521k | $51k | $462k | $4.3m | $8.5m | $4.2m | $6.7m | $14.3m | $30.4m | $45.8m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.